Guest guest Posted July 10, 2004 Report Share Posted July 10, 2004 The side effects listed are only the ones Elan admits to....this does not look too great either. I remember waiting for Rebif to be approved a year earlier and that did not pan out to be the miracle drug. I would not get too excited yet. It may be getting alot of hype because the stocks are soaring!! Antegren (natalizumab)Natalizumab, a humanized monoclonal antibody, is the first alpha-4 antagonist in the new SAM (selective adhesion molecule) inhibitor class. The drug was designed to selectively inhibit immune cells from leaving the bloodstream and to prevent these cells from migrating into chronically inflamed tissue as occurs in a variety of inflammatory diseases. To date, approximately 2,800 patients have received natalizumab in clinical studies. In previous clinical trials, the following adverse events occurred more commonly with natalizumab when compared to placebo: headache, nausea, abdominal pain, infection, urinary tract infection, pharyngitis and rash. Serious adverse events have included infrequent hypersensitivity-like reactions. Source: Elan Corporation, plc Quote Link to comment Share on other sites More sharing options...
Guest guest Posted July 10, 2004 Report Share Posted July 10, 2004 Urinary tract infections; just what people with MS need... ----- Original Message ----- From: noclue915@... low dose naltrexone Sent: Saturday, July 10, 2004 1:20 PM Subject: [low dose naltrexone] Antegren The side effects listed are only the ones Elan admits to....this does not look too great either. I remember waiting for Rebif to be approved a year earlier and that did not pan out to be the miracle drug. I would not get too excited yet. It may be getting alot of hype because the stocks are soaring!! Antegren (natalizumab)Natalizumab, a humanized monoclonal antibody, is the first alpha-4 antagonist in the new SAM (selective adhesion molecule) inhibitor class. The drug was designed to selectively inhibit immune cells from leaving the bloodstream and to prevent these cells from migrating into chronically inflamed tissue as occurs in a variety of inflammatory diseases. To date, approximately 2,800 patients have received natalizumab in clinical studies. In previous clinical trials, the following adverse events occurred more commonly with natalizumab when compared to placebo: headache, nausea, abdominal pain, infection, urinary tract infection, pharyngitis and rash. Serious adverse events have included infrequent hypersensitivity-like reactions. Source: Elan Corporation, plc Quote Link to comment Share on other sites More sharing options...
Recommended Posts
Join the conversation
You are posting as a guest. If you have an account, sign in now to post with your account.
Note: Your post will require moderator approval before it will be visible.